RVNC Revance Therapeutics Inc.

26.10
+0.00  (0%)
Previous Close 26.10
Open 26.10
Price To book 5.05
Market Cap 804380833
Shares 30,819,189
Volume 106,907
Short Ratio 26.96
Av. Daily Volume 147,152

SEC filingsSee all SEC filings

  1. 8-K - Current report 171071682
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171009415
  3. 8-K - Current report 171005049
  4. 8-K - Current report 171001065
  5. 8-K - Current report 17893053

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RT002 - SAKURA 2
Moderate to severe glabellar (frown) lines
Phase 2 completion of enrollment noted October 18, 2017. Data due towards the end of 2017.
RT002
Plantar fasciitis
Phase 3 endpoints not met June 2016
RT001 - REALISE 1
Lateral Canthal (Crow’s Feet) Lines
Phase 2 additional data released May 18, 2017 with additional data released June 5, 2017.
RT002
Cervical dystonia
Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RT002 - SAKURA 1
Moderate to severe glabellar (frown) lines

Latest News

  1. Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017
  2. ETFs with exposure to Revance Therapeutics, Inc. : October 18, 2017
  3. Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
  4. ETFs with exposure to Revance Therapeutics, Inc. : September 19, 2017
  5. Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference
  6. Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
  7. Revance Appoints Mark Foley to its Board of Directors
  8. Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : September 1, 2017
  9. Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference
  10. Edited Transcript of RVNC earnings conference call or presentation 9-May-17 8:30pm GMT
  11. Revance Releases Second Quarter 2017 Results
  12. Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics
  13. Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : July 31, 2017
  14. Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017
  15. Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : July 17, 2017
  16. Biotech Movers: Sangamo, Epizyme, Revance
  17. Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery
  18. Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial
  19. Revance to Participate in Upcoming Investor Conferences

SEC Filings

  1. 8-K - Current report 171071682
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171009415
  3. 8-K - Current report 171005049
  4. 8-K - Current report 171001065
  5. 8-K - Current report 17893053
  6. 8-K - Current report 17891244
  7. CT ORDER - Confidential treatment order 17866406
  8. CT ORDER - Confidential treatment order 17862965
  9. CT ORDER - Confidential treatment order 17859552
  10. 8-K - Current report 17855163